Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino }-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the beta 2 adrenergic receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one lack a water-soluble and stable salt form, making it difficult to create effective aqueous solutions suitable for administration to children and the elderly for treating respiratory diseases.
Innovation Solution
Development of methanesulphonic acid salts of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, which are highly soluble and stable in aqueous solutions, allowing for the creation of pharmaceutical compositions suitable for inhalation in treating respiratory diseases like asthma and chronic obstructive pulmonary disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If napadisylate salts of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one are used, then the compound can be administered by inhalation, but the salt lacks adequate water solubility and stability in aqueous solutions
Solution Approach 1:
The patent applies parameter changes by selecting a specific counterion (mesylate/methanesulphonate) to transform the compound into a salt form that simultaneously achieves high water solubility and stability. This chemical parameter modification resolves the contradiction between solubility and stability that plagued previous salt forms.
Solution Approach 2:
The mesylate salt acts as an intermediary form that bridges the gap between the parent compound's pharmacological activity and the requirements for aqueous formulation. This intermediate salt form enables the compound to be dissolved and stabilized in water while maintaining its therapeutic efficacy.
2Ease of operation
If a water-soluble salt form is developed for administration to children and the elderly, then ease of administration is improved, but the compound previously lacked a stable salt form suitable for aqueous solutions
Solution Approach 1:
By changing the salt form parameter to mesylate, the invention creates a compound that is both water-soluble and stable, thereby enabling easy administration to pediatric and geriatric patients who require liquid formulations while simultaneously achieving the previously elusive stability in aqueous solutions.
3Duration of action of stationary object
If adequate shelf-life is required for commercial distribution, then the product must be stable in aqueous formulations, but no water-soluble salt with desired stability has been reported
Solution Approach 1:
The invention resolves the shelf-life versus solubility contradiction by modifying the chemical parameter of the salt form to mesylate, which confers both high water solubility and exceptional stability in aqueous formulations, thereby achieving adequate shelf-life for commercial distribution while maintaining the necessary solubility characteristics.
Data Source
Figure 1
AI summary
The present invention is directed to a mesylate salt of 5-(2-{[6-(2,2-difluoro-2- phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1 H)-one and pharmaceutically acceptable solvates thereof.